The Importance of Early Recognition of Tay-Sachs and Sandhoff Disease
Released On
July 26, 2023
Expires On
July 26, 2024
Media Type
Internet
Completion Time
45 minutes
Specialty
Genetics, Neurology, Pediatrics, Primary Care, Psychiatry
Topic(s)
Rare disease
This activity is supported by an educational grant from Sanofi.
Credit Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
- Physician Associate - 0.75 AAPA Category 1 Hour
- Nurses — 0.75 Contact Hours
- CA-BRN — 0.75 Contact Hours (0.25 pharmacology hour)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity was developed for a national audience of neurologists, family physicians, internists, geneticists, psychiatrists, psychologists, advanced practice providers, and other clinicians who diagnose or manage patients with GM2 gangliosidoses (Tay-Sachs and Sandhoff Disease).
Program Overview
Faculty experts, Jeanine Jarnes, PharmD, and Chester Whitley, MD, PhD delve into the rare and difficult to diagnose GM2-gangliosidoses Tays-Sachs and Sandhoff diseases. Following a discussion of the etiology and pathophysiology of these diseases, the faculty use real-life cases to illustrate the various phenotypes of these conditions, as well as key presenting signs and symptoms. Diagnostic approaches are discussed, alongside current standards of care, including supportive and palliative treatment options. Drs. Jarnes and Whitley describe key therapeutic approaches under investigation to improve outcomes of patients with Tay-Sachs and Sandhoff disease.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify the most common presenting signs and symptoms of GM2 gangliosidoses
- Differentiate GM2 gangliosidoses from other possible diagnoses
- Classify emerging treatments for the GM2 gangliosidoses
Faculty
Jeanine Jarnes, PharmD, MSc, BCOP, BCPS
Assistant Professor, Department of Pediatrics
University of Minnesota Medical School
Pharmacotherapy for Inherited Metabolic Diseases
Advanced Therapies Department
College of Pharmacy, Experimental and Clinical Pharmacology
Minneapolis, Minnesota
Chester B. Whitley, MD, PhD
Professor
Medical Director, Advanced Therapies Program
Director, Gene Therapy Center
Director, PKU Clinic
Departments of Pediatrics, and
Experimental and Clinical Pharmacology
College of Pharmacy
University of Minnesota
Minneapolis, Minnesota
Accreditation Statement
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit
The Annenberg Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate Credit
The Annenberg Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until 7/26/24 PAs should only claim credit commensurate with the extent of their participation.
Nursing Credit
The Annenberg Center designates this education for a maximum of 0.75American Nurses Credentialing Center (ANCC) contact hours, including 0.25 pharmacology hour.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hours. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Disclosures of Conflicts of Interest
It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relationships with ACCME-defined ineligible companies.
The Annenberg Center assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant financial relationships that are identified are mitigated by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
- Jeanine Jarnes, PharmD, MSc
- Consultant: Lysogene, Passage Bio, Sio
The following have no significant relationship to disclose:
Chester B. Whitley, MD, PhD
Additional content planners
The following have no relevant financial relationship to disclose:
Sunali Wadehra, MD Medical Writer
Kam Newman, MD (Peer Reviewer)
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Planner)
Annenberg Center for Health Sciences
All staff at the Annenberg Center have no relevant financial relationships to disclose.
All the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Disclaimer
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center for Health Sciences at Eisenhower disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information
For CME questions please contact: ce@annenberg.net.